Information Provided By: 
Fly News Breaks for November 1, 2019
XENT
Nov 1, 2019 | 13:51 EDT
Piper Jaffray analyst Matt O'Brien called Intersect ENT's third quarter results "a positive first step in the right direction," but he needs to see more than one quarter of stable execution before becoming more constructive on the stock. He notes that Q3 revenue that was largely in-line with consensus expectations and said his "big takeaway" from the company's report was the healthy implied demand for PROPEL. O'Brien raised his price target on Intersect ENT shares to $21 from $17 but keeps a Neutral rating on the stock.
News For XENT From the Last 2 Days
There are no results for your query XENT
